Scholarlink

<p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that causes significant physical and psychosocial burden. Although U.S. Food and Drug Administration (FDA)-approved biologic therapies targeting tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) have improved outcomes for many patients with moderate-to-severe HS, a subset remain refractory or experience loss of response over time. Transcriptomic and immunologic studies demonstrate concurrent activation of multiple inflammatory pathways in HS, including TNF-α, IL-1, IL-17, and Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling, supporting a rationale for dual targeted therapy (DTT). This narrative review summarizes the current evidence on DTT in HS and contextualizes these findings with data from other immune-mediated diseases such as inflammatory bowel disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis. Published HS-specific reports remain limited to case reports of dual biologic or biologic plus Janus kinase (JAK) inhibitor therapy, each showing clinical improvement without serious short-term adverse events. Evidence from related immune-mediated diseases suggests that combined blockade of complementary cytokine pathways can enhance efficacy with acceptable safety in selected patients. DTT may represent a promising approach for treatment-resistant HS, warranting further prospective evaluation to understand optimal combinations, safety profiles, and long-term outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dual Targeted Therapy for Hidradenitis Suppurativa: A Narrative Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月24日

查看全文
  • Kenan Kherallah,
  • Claire S. Chung,
  • Raveena Ghanshani,
  • Alexandra Charrow,
  • Julia M. Riley,
  • Christopher J. Sayed,
  • Vivian Y. Shi,
  • Katrina H. Lee,
  • Jennifer L. Hsiao

摘要

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that causes significant physical and psychosocial burden. Although U.S. Food and Drug Administration (FDA)-approved biologic therapies targeting tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) have improved outcomes for many patients with moderate-to-severe HS, a subset remain refractory or experience loss of response over time. Transcriptomic and immunologic studies demonstrate concurrent activation of multiple inflammatory pathways in HS, including TNF-α, IL-1, IL-17, and Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling, supporting a rationale for dual targeted therapy (DTT). This narrative review summarizes the current evidence on DTT in HS and contextualizes these findings with data from other immune-mediated diseases such as inflammatory bowel disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis. Published HS-specific reports remain limited to case reports of dual biologic or biologic plus Janus kinase (JAK) inhibitor therapy, each showing clinical improvement without serious short-term adverse events. Evidence from related immune-mediated diseases suggests that combined blockade of complementary cytokine pathways can enhance efficacy with acceptable safety in selected patients. DTT may represent a promising approach for treatment-resistant HS, warranting further prospective evaluation to understand optimal combinations, safety profiles, and long-term outcomes.